SINOVAC Biotech Ltd. announced CoronaVac, SINOVACs COVID-19 vaccine, has started being used among the child population in China. A study on immune persistency was conducted in 180 volunteers in a phase II clinical study on a group of participants ranging from 3 to 17 years of age. The results showed that, three months after two doses of the vaccine, the seroconversion rates for children and adolescents were 98.9% and 100%, respectively. The geometric mean titer (GMT) of neutralizing antibody was close to the level recorded at 28 days after vaccination and remained significantly higher than the level recorded in adults and elderly at 28 days after vaccination. This indicates that CoronaVac has stable and good immunogenicity among the pediatric and adolescent population, recording better results compared to those in people aged 18 and above. CoronaVac was approved for emergency use on May 28, 2021 in China. SINOVACs COVID-19 vaccine had also been filed for use in Indonesia and was approved for use in the population of 12 to 17 years of age by Indonesian authorities in June 2021. The Lancet Infectious Diseases has published results from the Phase I/II clinical trials of an inactivated COVID-19 vaccine developed by SINOVAC, also known as CoronaVac®, in healthy children aged 3 to 17 years of age in China.